Literature DB >> 10860933

Inhibition of cell surface expression by mutant receptors demonstrates that D2 dopamine receptors exist as oligomers in the cell.

S P Lee1, B F O'Dowd, G Y Ng, G Varghese, H Akil, A Mansour, T Nguyen, S R George.   

Abstract

Numerous mutant G protein-coupled receptors with diminished or no function have been described that are naturally occurring or that are the product of gene manipulation. It has largely been assumed that receptor mutants do not affect the function of the wild-type receptor; however, the occurrence of G protein-coupled receptor dimerization suggests the possibility that an intermolecular interaction between mutant and wild-type receptors can occur. We have shown previously that the D2 dopamine receptor (D2DR) exists as dimers in cell lines and brain tissue. In this study, we demonstrated that mutant D2DR can modulate the function of the wild-type D2DR. While attempting to elucidate the structure of the D2DR dimer, we demonstrated that nonfunctional D2DR substitution and truncation mutants antagonized wild-type D2DR function. Furthermore, from analyses of this interaction between the receptor mutants and the D2DR, using photoaffinity labeling, we provide evidence that the D2DR is oligomeric in the cell.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10860933     DOI: 10.1124/mol.58.1.120

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  25 in total

Review 1.  Oligomerization of G protein-coupled receptors: past, present, and future.

Authors:  Paul S-H Park; Slawomir Filipek; James W Wells; Krzysztof Palczewski
Journal:  Biochemistry       Date:  2004-12-21       Impact factor: 3.162

Review 2.  Computational methods in drug design: modeling G protein-coupled receptor monomers, dimers, and oligomers.

Authors:  Patricia H Reggio
Journal:  AAPS J       Date:  2006-05-12       Impact factor: 4.009

3.  Transmembrane segment peptides can disrupt cholecystokinin receptor oligomerization without affecting receptor function.

Authors:  Kaleeckal G Harikumar; Maoqing Dong; Zhijie Cheng; Delia I Pinon; Terry P Lybrand; Laurence J Miller
Journal:  Biochemistry       Date:  2006-12-12       Impact factor: 3.162

4.  Asymmetric conformational changes in a GPCR dimer controlled by G-proteins.

Authors:  Marjorie Damian; Aimée Martin; Danielle Mesnier; Jean-Philippe Pin; Jean-Louis Banères
Journal:  EMBO J       Date:  2006-11-30       Impact factor: 11.598

5.  Follice-stimulating hormone receptor forms oligomers and shows evidence of carboxyl-terminal proteolytic processing.

Authors:  Richard M Thomas; Cheryl A Nechamen; Joseph E Mazurkiewicz; Marco Muda; Stephen Palmer; James A Dias
Journal:  Endocrinology       Date:  2007-02-01       Impact factor: 4.736

6.  Secretin receptor oligomers form intracellularly during maturation through receptor core domains.

Authors:  Cayle S Lisenbee; Laurence J Miller
Journal:  Biochemistry       Date:  2006-07-11       Impact factor: 3.162

7.  PNA-Based Multivalent Scaffolds Activate the Dopamine D2 Receptor.

Authors:  Andrew V Dix; Jennie L Conroy; Kara M George Rosenker; David R Sibley; Daniel H Appella
Journal:  ACS Med Chem Lett       Date:  2015-03-13       Impact factor: 4.345

8.  Novel bivalent ligands for D2/D3 dopamine receptors: Significant co-operative gain in D2 affinity and potency.

Authors:  Sanjib Gogoi; Swati Biswas; Gyan Modi; Tamara Antonio; Maarten E A Reith; Aloke K Dutta
Journal:  ACS Med Chem Lett       Date:  2012-10-26       Impact factor: 4.345

9.  Dopamine receptor expression and distribution dynamically change in the rat nucleus accumbens after withdrawal from cocaine self-administration.

Authors:  K L Conrad; K Ford; M Marinelli; M E Wolf
Journal:  Neuroscience       Date:  2010-05-07       Impact factor: 3.590

10.  Chaperones contribute to G protein coupled receptor oligomerization, but do not participate in assembly of the G protein with the receptor signaling complex.

Authors:  Maha M Hammad; Denis J Dupré
Journal:  J Mol Signal       Date:  2010-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.